Back to category hubs
CATEGORY HUB
FDA-approved peptide drug or regulated peptide/hormone medication
This hub separates regulatory meaning from marketing shorthand. Registered, listed, submitted, compounded, cosmetic-listed, or research-use-only does not automatically mean FDA-approved.
Registered is not approved
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
DMF submitted is not approved
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
Cosmetic listed is not clinically proven
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
Matching entries
| Peptide | Evidence | Regulatory | Safety | Reviewed |
|---|---|---|---|---|
| Abaloparatide Parathyroid hormone-related peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Angiotensin II Vasoactive peptide hormone | A | Approved | 5/5 | 6/22/2026 |
| Bivalirudin Direct thrombin inhibitor peptide | A | Approved | 4/5 | 6/22/2026 |
| Bremelanotide Melanocortin receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Calcitonin salmon Calcitonin peptide hormone | A | Approved | 4/5 | 6/22/2026 |
| Cetrorelix GnRH antagonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Cosyntropin ACTH analog peptide | A | Approved | 4/5 | 6/22/2026 |
| Dasiglucagon Glucagon analog | A | Approved | 4/5 | 6/22/2026 |
| Degarelix GnRH antagonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Desmopressin Vasopressin analog | A | Approved | 4/5 | 6/22/2026 |
| Dulaglutide GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Enfuvirtide HIV fusion inhibitor peptide | A | Approved | 4/5 | 6/22/2026 |
| Eptifibatide Cyclic heptapeptide antiplatelet | A | Approved | 4/5 | 6/22/2026 |
| Exenatide GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Ganirelix GnRH antagonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Glucagon Peptide hormone | A | Approved | 4/5 | 6/22/2026 |
| Goserelin GnRH agonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| HCG Glycoprotein hormone | A | Approved | 4/5 | 6/22/2026 |
| Icatibant Bradykinin B2 receptor antagonist peptide mimetic | A | Approved | 4/5 | 6/22/2026 |
| Insulin Peptide hormone / biologic-style medication | A | Approved | 4/5 | 6/22/2026 |
| Lanreotide Somatostatin analog | A | Approved | 4/5 | 6/22/2026 |
| Leuprolide GnRH agonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Linaclotide Guanylate cyclase-C agonist peptide | A | Approved | 4/5 | 6/22/2026 |
| Liraglutide GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Lixisenatide GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Nafarelin GnRH agonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Nesiritide Natriuretic peptide | A | Approved | 4/5 | 6/22/2026 |
| Octreotide Somatostatin analog | A | Approved | 4/5 | 6/22/2026 |
| Oxytocin Peptide hormone | A | Approved | 4/5 | 6/22/2026 |
| Pasireotide Somatostatin analog | A | Approved | 4/5 | 6/22/2026 |
| Plecanatide Guanylate cyclase-C agonist peptide | A | Approved | 4/5 | 6/22/2026 |
| Pramlintide Amylin analog | A | Approved | 4/5 | 6/22/2026 |
| Secretin human Gastrointestinal peptide hormone | A | Approved | 4/5 | 6/22/2026 |
| Semaglutide GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Setmelanotide Melanocortin-4 receptor agonist peptide | A | Approved | 4/5 | 6/22/2026 |
| Teduglutide GLP-2 analog | A | Approved | 4/5 | 6/22/2026 |
| Teriparatide Parathyroid hormone analog | A | Approved | 4/5 | 6/22/2026 |
| Tesamorelin Growth hormone-releasing hormone analog | A | Approved | 4/5 | 6/22/2026 |
| Tirzepatide Dual GIP and GLP-1 receptor agonist | A | Approved | 4/5 | 6/22/2026 |
| Triptorelin GnRH agonist peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Vasopressin Peptide hormone | A | Approved | 5/5 | 6/22/2026 |
| Vosoritide C-type natriuretic peptide analog | A | Approved | 4/5 | 6/22/2026 |
| Ziconotide Conopeptide calcium-channel blocker | A | Approved | 4/5 | 6/22/2026 |